| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Feb, 2026 | Feb, 2026 |
| Sales | 1,140 | 200 | 190 | 0 | 0 |
| Sales Growth | +470.00% | +5.26% | unch | unch | unch |
| Net Income | -88,040 | -48,610 | -35,440 | 0 | 0 |
| Net Income Growth | -81.12% | -37.16% | unch | unch | unch |
Cg Oncology Inc
(CGON)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology is based in IRVINE, Calif.
Fiscal Year End Date: 12/31